Stock listing

Xetra:KK3A Cytokinetics, Incorporated Aktie

German listing (Xetra) of Cytokinetics, Incorporated · home listing NASDAQ:CYTK

Follow Cytokinetics, Incorporated into a list and get an email when it puts out news.

Home listing price · NASDAQ:CYTK

$50.78 USD -0.54 (-1.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CYTK

Past year -20.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$50.60 – $53.38 USDNov 20, 2026
Volume
1.43M sharesNov 20, 2026
Market cap
$7.07B USDAt the close on Nov 20, 2026 · price × 139.3M shares outstanding
52-week range
$50.60 – $88.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$129.5M USDMedian day 1.72M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cytokinetics, Incorporated logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CYTK · Home$50.78 USD-0.54 (-1.1%)1,426,568$51.23$53.38$50.60$51.32Close on Nov 20, 2026
Frankfurt:KK3A€45.69 EUR-0.76 (-1.6%)—€46.06€46.06€45.69€46.45Close on Nov 20, 2026
Munich:KK3A€46.87 EUR-1.10 (-2.3%)—€46.87€46.87€46.87€47.97Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CYTK · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$50.78-0.54-1.1%$51.23$53.38$50.601,426,568
$51.32-0.33-0.6%$51.30$52.84$51.041,594,452
$51.65-1.52-2.9%$52.68$52.90$51.382,711,974
$53.17-2.96-5.3%$55.39$55.62$52.681,754,721
$56.13-0.03-0.1%$56.15$56.66$55.151,013,535
$56.16-2.37-4.0%$58.30$58.58$55.672,008,636
$58.53+2.35+4.2%$56.40$59.08$55.742,810,649
$56.18+1.04+1.9%$54.67$57.21$54.122,357,528
$55.14+1.45+2.7%$54.50$55.85$53.583,119,164
$53.69-1.86-3.3%$55.70$56.51$53.552,560,975
$55.55-8.05-12.7%$60.04$60.84$54.166,774,495
$63.60+1.29+2.1%$64.06$64.95$60.982,686,320
$62.31+0.28+0.5%$62.74$64.37$62.051,699,286
$62.03-0.96-1.5%$63.40$64.00$61.971,559,905
$62.99-0.32-0.5%$63.44$64.50$62.551,257,092
$63.31+2.03+3.3%$62.08$63.92$61.541,425,387
$61.28-0.24-0.4%$60.86$61.39$60.151,274,147
$61.52+0.79+1.3%$60.68$61.82$60.471,147,815
$60.73-0.50-0.8%$61.45$61.89$60.49783,222
$61.23-1.10-1.8%$62.01$62.44$60.89985,434
$62.33-0.53-0.8%$63.01$64.07$61.942,061,246
$62.86-1.09-1.7%$64.30$64.78$62.461,080,574
$63.95+1.30+2.1%$63.13$64.76$62.881,050,368
$62.65+0.70+1.1%$62.06$63.61$61.841,912,775
$61.95-1.97-3.1%$63.90$63.90$61.691,204,400
$63.92+0.49+0.8%$64.81$65.57$63.811,665,100
$63.43+1.81+2.9%$61.62$64.01$60.992,095,700
$61.62-1.17-1.9%$62.32$63.05$61.501,936,000
$62.79-0.12-0.2%$62.48$63.50$62.131,253,900
$62.91+0.90+1.5%$61.87$63.03$61.591,118,500
$62.01+0.89+1.5%$60.31$62.79$59.792,594,600
$61.12-0.23-0.4%$61.09$62.05$60.152,395,600
$61.35-1.35-2.2%$62.20$62.53$60.683,228,900
$62.70-2.90-4.4%$65.60$65.76$62.193,234,300
$65.60-0.020.0%$66.45$66.91$64.492,649,900
$65.62-0.29-0.4%$65.73$67.27$65.301,724,300
$65.91+0.27+0.4%$65.90$66.92$65.252,977,700
$65.64-0.52-0.8%$65.91$66.52$64.382,401,400
$66.16+1.50+2.3%$64.58$66.41$64.252,551,200
$64.66-1.00-1.5%$65.66$65.95$64.441,599,200
$65.66-0.15-0.2%$65.37$66.47$64.891,836,300
$65.81-1.78-2.6%$67.02$67.39$64.732,050,900
$67.59+0.030.0%$68.07$69.56$67.482,388,500
$67.56-1.22-1.8%$69.30$69.50$67.351,603,400
$68.78-1.14-1.6%$70.18$70.18$68.154,873,000
$69.92+0.53+0.8%$70.64$71.05$68.921,398,200
$69.39+0.08+0.1%$69.52$70.68$68.672,211,800
$69.31-3.14-4.3%$72.13$72.19$68.552,576,600
$72.45-1.32-1.8%$73.51$74.65$72.341,533,500
$73.77+0.15+0.2%$74.66$75.98$73.501,721,500
$73.62-0.49-0.7%$73.23$75.10$73.131,444,900
$74.11-1.24-1.6%$74.31$74.89$73.521,424,800
$75.35+2.63+3.6%$72.39$76.81$72.391,920,900
$72.72-1.23-1.7%$73.04$74.01$72.261,140,900
$73.95+2.02+2.8%$73.55$74.23$71.411,589,700
$71.93+0.53+0.7%$71.90$73.70$70.421,605,700
$71.40+0.49+0.7%$69.85$72.46$69.831,898,300
$70.91-1.18-1.6%$71.54$71.79$69.313,078,100
$72.09-5.81-7.5%$73.88$74.42$71.664,361,500
$77.90-1.30-1.6%$78.84$79.13$77.841,109,800
$79.20+1.74+2.2%$77.91$79.88$76.701,236,600
$77.46+0.37+0.5%$77.93$78.72$77.211,260,832
$77.09+0.25+0.3%$77.20$77.99$75.651,212,285
$76.84-0.34-0.4%$77.30$77.70$76.651,521,300
$77.18-0.56-0.7%$77.36$77.62$76.141,651,700

Splits

1 split · NASDAQ:CYTK · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
Ticker
Xetra:KK3A
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All Cytokinetics, Incorporated news

Cytokinetics, Incorporated on 6ix

Sector
Health care
Industry
Biotechnology
News releases
45 in the last 12 months · 299 in all · newest Nov 16, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Nov 4, 2026
Decks
57 decks · latest October 2026

Where Cytokinetics, Incorporated is listed

ListingExchangeCountryCurrency
NASDAQ:CYTK · Home listingNASDAQUnited StatesUSD
gettex:KK3AgettexGermanyEUR
LS Exchange:A1W1KKLS ExchangeGermanyEUR
Lang & Schwarz:A1W1KKLang & SchwarzGermanyEUR
BOATS:CYTKBOATSUnited StatesUSD
Tradegate:KK3ATradegateGermanyEUR
Milan:1CYTKMilanItalyEUR
Frankfurt:KK3AFrankfurtGermanyEUR
BX Swiss:KK3ABX SwissSwitzerlandCHF
Dusseldorf:KK3ADusseldorfGermanyEUR
Hamburg:KK3AHamburgGermanyEUR
Munich:KK3AMunichGermanyEUR
Stuttgart:KK3AStuttgartGermanyEUR
Hanover:KK3AHanoverGermanyEUR
Xetra:KK3A · This pageXetraGermanyEUR

Valuation

EV/sales 56.2× against a median of 13.5×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$6.36B USD
P/E
Loss
EV/sales
56.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
93.9%
Operating margin
−625.1%
Net margin
−686.6%
Debt to equity
Negative equity
Beta vs S&P 500
0.93

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Summit Therapeutics Inc. · NASDAQ:SMMTUS$7.96BUS$7.33Bn/an/an/a14.1×n/a0.0×1.91
Protagonist Therapeutics, Inc. · NASDAQ:PTGXUS$7.92BUS$7.13B23.1×12.9×22.0×7.3×62.0%0.0×0.93
Alkermes plc · NASDAQ:ALKSUS$7.55BUS$8.31Bn/a4.7×57.3×4.0×−0.0%0.8×0.80
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Median of the othersUS$6.73BUS$6.21B23.1×13.5×39.6×7.3×−18.2%0.0×1.30

Forecasts

13 strong buy · 7 buy · 2 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
109.42 USD · Analysts' mean
EPS, year to Dec 2026
-5.76 · 17 analysts
Revenue, year to Dec 2026
163.7M · 19 analysts

Team and board

Officers

OfficerRole
Robert I. BlumPresident and Chief Executive Officer
Sung LeeEVP, Chief Financial Officer
Jeff HessekielEVP, Chief Legal & Administrative Officer
John FaurescuSVP, Deputy General Counsel & Corporate Secretary
Andrew CallosEVP, Chief Commercial Officer
Diane WeiserSVP, Corporate Affairs
Elisabeth A. SchniedersSVP, Business Development
Fady I. MalikEVP, Research & Development
Isaac CiechanoverEVP, Corporate Development & Chief Business Officer
Stephen B. HeitnerSVP, Chief Medical Officer
Tricia OttavianiSVP, U.S. & Global Marketing and Operations

Board

DirectorRole
John T. HendersonChairman
B. Lynne ParshallDirector
Edward M. KayeDirector
Jim DalyDirector
Muna BhanjiDirector
Nancy J. WysenskiDirector
Robert A. HarringtonDirector
Robert LandryDirector
Wendell WierengaDirector

Events

Calls

CallWhenStatus
Cytokinetics (NASDAQ:CYTK) Q3 2026 Earnings CallWed, Nov 04, 2026 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q2 2026 Earnings CallThu, Aug 06, 2026 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q1 2026 Earnings CallTue, May 05, 2026 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q4 2025 Earnings CallTue, Feb 24, 2026 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q4 2026 Earnings CallTue, Feb 24, 2026 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q3 2025 Earnings CallWed, Nov 05, 2025 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q1 2025 Earnings CallTue, May 06, 2025 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q4 2024 Earnings CallThu, Feb 27, 2025 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q3 2024 Earnings CallWed, Nov 06, 2024 · 4:30 PM ETReplay
All 26 calls
CallWhenStatus
Cytokinetics (NASDAQ:CYTK) Q2 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q1 2024 Earnings CallWed, May 08, 2024 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q4 2023 Earnings CallTue, Feb 27, 2024 · 4:00 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q3 2023 Earnings CallThu, Nov 02, 2023 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q2 2023 Earnings CallThu, Aug 03, 2023 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q1 2023 Earnings CallThu, May 04, 2023 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q4 2022 Earnings CallWed, Mar 01, 2023 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q3 2021 Earnings CallWed, Nov 03, 2021 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q2 2021 Earnings CallThu, Aug 05, 2021 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q1 2021 Earnings CallThu, May 06, 2021 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q4 2020 Earnings CallThu, Feb 25, 2021 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q3 2020 Earnings CallWed, Nov 04, 2020 · 4:30 PM ETReplay
Cytokinetics (NASDAQ:CYTK) Q2 2020 Earnings CallThu, Aug 06, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−12.7%
Q2 2026Aug 6, 2026 · After close−5.7%
Q1 2026May 5, 2026 · After close−2.9%
Q4 2025Feb 24, 2026−7.9%
Q3 2025Nov 5, 2025 · After close+1.9%
Q2 2025Aug 7, 2025 · After close−3.2%
Q1 2025May 6, 2025 · After close−2.7%
Q4 2024Feb 25, 2025 · After close+0.5%
Q3 2024Nov 6, 2024 · After close+0.6%
Q2 2024Aug 8, 2024 · After close+3.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−1.9%
Q4 2023Feb 27, 2024 · After close−9.8%
Q3 2023Nov 2, 2023 · After close+4.8%
Q2 2023Aug 2, 2023 · After close+2.0%
Q1 2023May 4, 2023 · After close+0.4%
Q4 2022Mar 1, 2023 · After close−8.1%
Q3 2022Nov 3, 2022 · After close−5.0%
Q2 2022Aug 4, 2022 · After close+10.9%
Q1 2022May 4, 2022 · After close−1.7%
Q4 2021Feb 24, 2022 · After close+3.1%

Open Events

Decks

DeckKindSlidesDate
HFSA Annual Scientific Meeting 2026Conference12 slidesOctober 2026
Investor Presentation (September 2026)Investor deck70 slidesSeptember 2026
Technical Presentation (August 2026)Technical20 slidesAug 29, 2026
Technical Presentation (August 2026)Technical15 slidesAug 29, 2026
Investor Presentation (August 2026)Investor deck65 slidesAugust 2026
Technical Presentation (August 2026)Technical23 slidesAugust 2026
Investor Presentation (May 2026)Investor deck63 slidesMay 19, 2026
Investor Presentation (May 2026)Investor deck37 slidesMay 5, 2026
Q1 2026 Earnings PresentationEarnings29 slidesMay 5, 2026
Investor Presentation (March 2026)Investor deck60 slidesMarch 2026
Show 50 decks
DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck57 slidesJanuary 2026
Investor Presentation (December 2025)Investor deck74 slidesDecember 2025
Technical Presentation (November 2025)Technical18 slidesNov 6, 2025
Technical Presentation (November 2025)Technical13 slidesNovember 2025
Technical Presentation (November 2025)Technical15 slidesNovember 2025
Technical Presentation (November 2025)Technical14 slidesNovember 2025
Investor Presentation (September 2025)Investor deck73 slidesSeptember 2025
ESC Congress 2025Conference10 slidesAug 31, 2025
Technical Presentation (August 2025)Technical8 slidesAug 31, 2025
Technical Presentation (August 2025)Technical18 slidesAug 30, 2025
Q1 2025 Earnings PresentationEarnings63 slidesMay 6, 2025
Investor Presentation (March 2025)Investor deck62 slidesMarch 2025
Investor Presentation (December 2024)Investor deck60 slidesDecember 2024
Investor Presentation (October 2024)Investor deck59 slidesOctober 2024
Investor Presentation (September 2024)Investor deck51 slidesSeptember 2024
Investor Presentation (July 2024)Investor deck52 slidesJuly 2024
Investor Presentation (June 2024)Investor deck73 slidesJune 2024
Investor Presentation (May 2024)Investor deck56 slidesMay 22, 2024
Investor Presentation (May 2024)Investor deck68 slidesMay 2024
Investor Presentation (May 2024)Investor deck63 slidesMay 2024
Investor Presentation (May 2024)Investor deck62 slidesMay 2024
Investor Presentation (March 2024)Investor deck59 slidesMarch 2024
Investor Presentation (January 2024)Investor deck58 slidesJanuary 2024
Investor Presentation (November 2023)Investor deck54 slidesNovember 2023
Investor Day (October 2023)Investor day125 slidesOct 19, 2023
Investor Presentation (October 2023)Investor deck46 slidesOctober 2023
Investor Presentation (September 2023)Investor deck45 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck47 slidesJune 2023
Investor Presentation (May 2023)Investor deck41 slidesMay 2023
Investor Presentation (March 2023)Investor deck43 slidesMarch 2023
Investor Presentation (January 2023)Investor deck52 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck58 slidesNovember 2022
Investor Presentation (July 2022)Investor deck57 slidesJuly 2022
Investor Presentation (June 2022)Investor deck61 slidesJun 1, 2022
Investor Presentation (April 2022)Investor deck63 slidesApril 2022
Investor Presentation (January 2022)Investor deck39 slidesJanuary 2022
Investor Day (October 2021)Investor day124 slidesOct 7, 2021
Investor Presentation (July 2021)Investor deck54 slidesJul 19, 2021
Investor Presentation (July 2021)Investor deck16 slidesJuly 2021
Investor Presentation (July 2021)Investor deck60 slidesJuly 2021

This page holds 50 of 57 decks. Open Decks

Open Decks

Financings

RaiseDate
1.75% convertible senior notes due 2031
Made bigger: US$650M
Use of proceeds: About $402.5M to exchange 2027 convertible notes; rest for aficamten launch and development, pipeline research and general corporate purposes
Sep 16, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue88.0M18.5M7.53M94.6M70.4M55.8M26.9M31.5M13.4M106.4M
Cost of revenue10.1M339.4M330.1M240.8M159.9M97.0M86.1M89.1M90.3M59.9M
Gross profit77.9M-320.9M-322.6M-146.2M-89.5M-41.1M-59.3M-57.6M-76.9M46.5M
Research and development416.0M339.4M330.1M240.8M159.9M97.0M86.1M89.1M90.3M59.9M
Selling, general and administrative284.3M215.3M173.6M178.0M96.8M52.8M39.6M31.3M36.5M27.8M
Operating income-612.3M-536.2M-496.2M-324.2M-186.3M-93.9M-98.9M-88.9M-113.4M18.7M
Depreciation and amortization10.1M9.53M11.9M5.81M2.28M1.83M1.29M1.24M1.92M741.0K
EBITDA-602.1M-526.7M-484.3M-318.4M-184.0M-92.1M-97.6M-87.7M-111.5M19.4M
Interest expense45.6M37.7M28.3M19.4M16.4M16.0M6.62M3.80M3.02M2.70M
Income before tax-785.0M-589.5M-526.2M-389.0M-215.3M-127.3M-121.7M-106.3M-127.8M16.5M
Income tax0000000000
Net income-785.0M-589.5M-526.2M-389.0M-215.3M-127.3M-121.7M-106.3M-127.8M16.5M
Earnings per share, basic-6.54-5.26-5.45-4.33-2.80-1.97-2.11-1.95-2.590.41
Earnings per share, diluted-6.54-5.26-5.45-4.33-2.80-1.97-2.11-1.95-2.590.39

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents122.5M94.9M113.0M65.6M112.7M83.0M36.4M42.3M125.2M66.9M
Short-term investments759.7M981.2M501.8M717.0M359.0M381.1M188.7M156.5M143.7M89.4M
Receivables17.8M16.6M1.28M147.0K51.8M4.42M5.16M2.23M1.11M24.0K
Inventory0-11.9M-147.0K-51.8M-4.42M-6.79M10
Current assets917.0M1.11B628.1M795.2M535.7M474.2M233.8M207.7M274.3M158.6M
Property, plant and equipment79.2M65.8M68.7M80.5M73.3M13.3M4.53M3.20M3.57M3.64M
Goodwill000
Total assets1.42B1.40B824.3M1.01B841.3M533.8M289.8M211.2M294.8M170.1M
Accounts payable22.3M20.4M21.5M25.6M21.1M8.05M8.16M3.76M5.25M4.24M
Current liabilities202.5M179.7M102.7M84.6M71.9M31.2M26.0M22.2M32.4M33.3M
Long-term debt246.4M93.2M58.4M63.8M47.4M46.2M45.1M39.8M31.8M27.4M
Total debt287.6M619.5M639.3M649.6M47.4M46.2M45.1M42.4M31.8M29.9M
Total liabilities2.08B1.54B1.21B1.12B597.5M420.4M300.8M185.2M185.0M75.8M
Shareholders' equity-659.6M-135.4M-386.3M-107.9M243.9M113.4M-10.9M25.9M109.8M94.4M
Shares outstanding122.9M118.2M101.6M94.8M84.8M71.0M59.2M54.7M54.0M40.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-510.0M-395.9M-414.3M-299.5M-142.5M8.94M-90.9M-101.2M-101.8M37.0M
Capital spending-24.8M-3.91M-1.42M-11.3M-48.9M-11.1M-2.62M-889.0K-2.88M-1.60M
Free cash flow-534.8M-399.8M-415.7M-310.9M-191.4M-2.11M-93.5M-102.1M-104.6M35.4M
Cash from investing16.7M-553.1M239.3M-262.1M-147.8M-196.5M-74.7M5.13M-65.8M-52.1M
Cash from financing524.5M930.6M221.3M516.2M320.0M234.1M159.8M13.1M225.9M16.9M
Dividends paid-18.5M000
Share buybacks53.0M-10.5M17.5M-4.45M-2.25M37.6M3.23M126.5M1.90M
Change in cash30.4M-18.2M46.2M-45.5M29.7M46.6M-5.82M-83.0M58.3M1.80M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
144 · Notice of proposed saleOct 20, 2026Other filingsSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
144 · Notice of proposed saleOct 13, 2026Other filingsSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 22, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
8-K · Current reportAug 28, 2026Current reportSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026Current reportSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
144 · Notice of proposed saleJul 30, 2026Other filingsSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 27, 2026Offer documentSEC
8-K · Current reportMay 27, 2026Meeting outcomeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
8-K · Current reportMay 8, 2026Current reportSEC
424B5 · ProspectusMay 7, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
424B5 · ProspectusMay 5, 2026Offer documentSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
8-K · Current reportMay 5, 2026Current reportSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
144 · Notice of proposed saleApr 7, 2026Other filingsSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
144 · Notice of proposed saleMar 18, 2026Other filingsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 24, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 17, 2026Current reportSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
144 · Notice of proposed saleDec 29, 2025Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
8-K · Current reportDec 19, 2025Current reportSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
8-K · Current reportDec 12, 2025Current reportSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
144 · Notice of proposed saleDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
144 · Notice of proposed saleDec 2, 2025Other filingsSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 14, 2025Insider tradeSEC
8-K · Current reportNov 14, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
8-K · Current reportNov 5, 2025ResultsSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC

This page holds 200 of 1,002 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cytokinetics, Incorporated’s releases · as of Nov 13, 2026

Common shares
139,303,351
Fully diluted
139,409,957

Fully diluted

LineSharesAs of
Common shares139,303,351Nov 2, 2026
Options and RSUs106,606Nov 13, 2026

Warrants and options

Lot
Stock options · US$56.13 · expire about Nov 2036
RSUs · expiry not stated

Share count over time

CountShares
Nov 2, 2026139,303,351

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock21MUS$1.39BSep 30, 2026
T. Rowe Price20.5MUS$1.35BSep 30, 2026
Vanguard14.2MUS$938MSep 30, 2026
Wellington10.6MUS$698MSep 30, 2026
Polar Capital Holdings Plc9.64MUS$228MSep 30, 2026
State Street7.14MUS$471MSep 30, 2026
Avoro Capital Advisors LLC4.9MUS$323MSep 30, 2026
Bank of America4.74MUS$312MSep 30, 2026
Geode Capital3.77MUS$248MSep 30, 2026
Invesco3.02MUS$199MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Capital Group2.86MUS$189MSep 30, 2026
Rtw Investments, LP2.86MUS$189MSep 30, 2026
Fidelity2.23MUS$147MSep 30, 2026
Goldman Sachs1.85MUS$122MSep 30, 2026
Schwab1.73MUS$114MSep 30, 2026
Northern Trust1.66MUS$109MSep 30, 2026
JPMorgan1.63MUS$108MSep 30, 2026
Integral Health Asset Management, LLC1.6MUS$72.5MSep 30, 2026
BNP Paribas1.59MUS$104MSep 30, 2026
William Blair Investment Management, LLC1.58MUS$104MSep 30, 2026
Two Sigma1.57MUS$103MSep 30, 2026
Pictet Asset Management Holding SA1.37MUS$90.6MSep 30, 2026
Morgan Stanley1.36MUS$89.8MSep 30, 2026
UBS1.25MUS$82.1MSep 30, 2026
Principal1.23MUS$80.8MSep 30, 2026
Armistice Capital, LLC1.18MUS$77.8MSep 30, 2026
BNY1.17MUS$77.2MSep 30, 2026
Woodline Partners LP1.1MUS$72.5MSep 30, 2026
Nomura1.08MUS$71.1MSep 30, 2026
Susquehanna1.04MUS$68.7MSep 30, 2026
Franklin Templeton1.04MUS$65.9MSep 30, 2026
GW&K Investment Management, LLC1.02MUS$67.1MSep 30, 2026
Royalty Pharma Sub-Manager, LLC980KUS$64.6MSep 30, 2026
Wcm Investment Management, LLC910KUS$59.8MSep 30, 2026
Hood River Capital Management LLC885KUS$58.3MSep 30, 2026
Fisher Asset Management, LLC819KUS$54MSep 30, 2026
Melqart Asset Management (UK) Ltd762KUS$50.2MSep 30, 2026
Affinity Asset Advisors, LLC750KUS$49.4MSep 30, 2026
Foresite Capital Management IV, LLC715KUS$47.1MSep 30, 2026
Siren, L.L.C.709KUS$46.7MSep 30, 2026
Nuveen706KUS$46.5MSep 30, 2026
Vaughan Nelson Investment Management, L.P.661KUS$43.6MSep 30, 2026
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.660KUS$43.5MSep 30, 2026
Candriam S.C.A.617KUS$40.8MSep 30, 2026
Eventide Asset Management, LLC565KUS$37.2MSep 30, 2026
Federated Hermes, Inc.549KUS$36.2MSep 30, 2026
AllianceBernstein529KUS$34.9MSep 30, 2026
Sun Life521KUS$34.3MSep 30, 2026
American Century520KUS$34.3MSep 30, 2026
Checkpoint Capital L.P.517KUS$34.1MSep 30, 2026

This page holds 50 of 458 holders. Open Shareholders

Funds

HolderSharesValueAs of
T. Rowe Price Capital Appreciation Fund6.29MUS$536MJun 30, 2026
iShares Core S&P Mid-Cap ETF4.65MUS$396MJun 30, 2026
Vanguard Total Stock Market Index Fund4.31MUS$368MJun 30, 2026
iShares Russell 2000 ETF3.39MUS$289MJun 30, 2026
Vanguard Health Care Fund3.34MUS$258MJul 31, 2026
Vanguard Small-Cap Index Fund3.11MUS$265MJun 30, 2026
SMALLCAP World Fund Inc3MUS$255MJun 30, 2026
Fidelity OTC Portfolio2.27MUS$175MJul 31, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.1.97MUS$168MJun 30, 2026
Vanguard Small-Cap Growth Index Fund1.79MUS$153MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Extended Market Index Fund1.56MUS$133MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.48MUS$126MJun 30, 2026
JNL/T. Rowe Price Capital Appreciation Fund1.45MUS$123MJun 30, 2026
Fidelity Small Cap Index Fund1.44MUS$111MJul 31, 2026
T. Rowe Price Capital Appreciation Equity ETF1.16MUS$98.9MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.1.13MUS$96.5MJun 30, 2026
iShares Russell 2000 Value ETF1.11MUS$94.3MJun 30, 2026
iShares Biotechnology ETF844KUS$71.9MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.798KUS$68MJun 30, 2026
Vanguard Explorer Fund701KUS$54.1MJul 31, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF687KUS$58.5MJun 30, 2026
Fidelity Extended Market Index Fund678KUS$52MMay 31, 2026
Vanguard Russell 2000 Index Fund665KUS$51MMay 31, 2026
Vy(R) T. Rowe Price Capital Appreciation Portfolio650KUS$55.4MJun 30, 2026
Schwab U.S. Small-Cap ETF635KUS$48.8MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio575KUS$44.2MMay 29, 2026
Eventide Healthcare & Life Sciences Fund564KUS$48MJun 30, 2026
Penn Series Flexibly Managed Fund465KUS$39.6MJun 30, 2026
Select Biotechnology Portfolio449KUS$34.5MMay 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund447KUS$38.1MJun 30, 2026
iShares S&P Mid-Cap 400 Growth ETF438KUS$37.3MJun 30, 2026
SmallCap Fund412KUS$31.7MJul 31, 2026
JPMorgan Mid Cap Growth Fund402KUS$34.2MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.395KUS$33.7MJun 30, 2026
Small Cap Growth Fund392KUS$30.2MJul 31, 2026
Schwab U.S. Mid-Cap ETF357KUS$27.4MMay 31, 2026
Vanguard Health Care Index Fund350KUS$26.9MMay 31, 2026
Fidelity Puritan Fund330KUS$25.3MMay 31, 2026
T. Rowe Price New Horizons Fund, Inc.329KUS$28MJun 30, 2026
Schwab Small-Cap Index Fund321KUS$24.8MJul 31, 2026
Federated Hermes Kaufmann Fund317KUS$24.4MJul 31, 2026
iShares S&P Mid-Cap 400 Value ETF313KUS$26.7MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund305KUS$23.4MMay 31, 2026
Fidelity Advisor Equity Growth Fund292KUS$22.4MMay 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund263KUS$22.4MJun 30, 2026
JNL/Invesco Small Cap Growth Fund259KUS$22.1MJun 30, 2026
Fidelity Total Market Index Fund250KUS$19.2MMay 31, 2026
Master Small Cap Index Series244KUS$20.8MJun 30, 2026
VIP Growth Portfolio237KUS$20.2MJun 30, 2026
Invesco Small Cap Growth Fund232KUS$19.8MJun 30, 2026

This page holds 50 of 497 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Hessekiel Jeffrey
Officer: Chief Legal & Admin Officer
Sale15,106USD 52.62US$795KNov 17, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,300USD 51.73US$171KNov 17, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale200USD 52.59US$10,518Nov 17, 2026
Blum Robert I
Director, Officer: President & CEO
Sale5,077USD 53.22US$270KNov 16, 2026
Blum Robert I
Director, Officer: President & CEO
Sale2,223USD 54.08US$120KNov 16, 2026
Blum Robert I
Director, Officer: President & CEO
Sale200USD 55.21US$11,042Nov 16, 2026
Parshall B Lynne
Director
Sale2,445USD 54.17US$132KNov 9, 2026
Parshall B Lynne
Director
Sale2,555USD 55.26US$141KNov 9, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 62.93US$220KNov 3, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 62.81US$471KNov 2, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 64.01US$224KOct 20, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 62.88US$472KOct 12, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 61.38US$215KOct 6, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 65.46US$491KSep 28, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 68.29US$239KSep 22, 2026
Blum Robert I
Director, Officer: President & CEO
Sale97,926USD 69.33US$6.79MSep 15, 2026
Landry Robert E
Director
Sale1,000USD 72.13US$72,130Sep 15, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 73.44US$551KSep 14, 2026
Landry Robert E
Director
Sale1,000USD 74.66US$74,660Sep 11, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 75.46US$264KSep 8, 2026
Parshall B Lynne
Director
Sale5,000USD 71.48US$357KSep 1, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 70.24US$527KAug 31, 2026
Callos Andrew
Officer: EVP, Chief Commercial Officer
Sale10,000USD 70.24US$702KAug 31, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 75.82US$265KAug 18, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 76.76US$576KAug 10, 2026
Callos Andrew
Officer: EVP, Chief Commercial Officer
Sale14,000USD 79.88US$1.12MJul 30, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 80.87US$607KJul 27, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 80.59US$282KJul 21, 2026
Blum Robert I
Director, Officer: President & CEO
Sale10USD 82.02US$820Jul 13, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,490USD 82.02US$614KJul 13, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 86.62US$303KJul 7, 2026
Lee Sung
Officer: EVP, Chief Financial Officer
Sale1,112USD 87.79US$97,622Jul 1, 2026
Callos Andrew
Officer: EVP, Chief Commercial Officer
Sale15,000USD 85.80US$1.29MJul 1, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 84.92US$637KJul 1, 2026
Lee Sung
Officer: EVP, Chief Financial Officer
Sale3,134USD 85.00US$266KJun 29, 2026
Lee Sung
Officer: EVP, Chief Financial Officer
Sale38,730USD 82.30US$3.19MJun 24, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 79.51US$278KJun 23, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 70.46US$528KJun 15, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 67.98US$238KJun 9, 2026
Parshall B Lynne
Director
Sale5,000USD 74.08US$370KJun 1, 2026
Callos Andrew
Officer: EVP, Chief Commercial Officer
Sale15,000USD 74.08US$1.11MJun 1, 2026
Kaye Edward M. MD
Director
Sale2,933USD 76.09US$223KJun 1, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 77.21US$579KMay 27, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 75.69US$265KMay 19, 2026
Blum Robert I
Director, Officer: President & CEO
Sale7,500USD 77.92US$584KMay 14, 2026
Callos Andrew
Officer: EVP, Chief Commercial Officer
Sale11,333USD 77.25US$875KMay 5, 2026
Henderson John T
Director
Sale20,000USD 75.97US$1.52MMay 5, 2026
Lee Sung
Officer: EVP, Chief Financial Officer
Sale23,906USD 76.87US$1.84MMay 5, 2026
Wierenga Wendell
Director
Sale4,032USD 75.00US$302KMay 5, 2026
Malik Fady Ibraham
Officer: EVP Research & Development
Sale3,500USD 77.37US$271KMay 5, 2026

This page holds 50 of 59 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
T. Rowe Price Investment Management, Inc.14.50%17.7MDec 31, 2025Schedule 13G
Wellington Management Group LLP7.70%10.7MSep 30, 2026Schedule 13G
Vanguard Capital Management LLC5.21%6.42MMar 31, 2026Schedule 13G
State Street Corp5.10%7.14MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Wendall Wierenga
Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2018); Concert Pharmaceuticals Inc (Director · Mar 13, 2014 – Jun 14, 2018 · Past); Apricus Biosciences Inc (Director · Mar 10, 2014 – Jan 4, 2018 · Past); Ocera Therapeutics Inc (Director · Dec 19, 2013 – Dec 11, 2017 · Past); Santarus Inc (EVP, R&D · Jun 20, 2011 – Jan 2, 2014 · Past); XenoPort Inc (Director · May 7, 2009 – Jul 5, 2016 · Past); Onyx Pharmaceuticals Inc (Director · Dec 15, 2008 – Oct 1, 2013 · Past)
Director · Since at least Feb 9, 2011
Lynne Parshall
Other companies: Foghorn Therapeutics Inc. (Director, Ionis Pharmaceuticals · Since at least Aug 16, 2022); Ionis Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2006); Akcea Therapeutics Inc (Director · Jul 13, 2017 – Oct 12, 2020 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Nov 3, 2014 · Past); Cardiodynamics International Corp (Director · Jul 20, 2006 – Aug 14, 2009 · Past)
Director · Since at least Feb 7, 2013
Santo J Costa
Other companies: Aquestive Therapeutics, Inc. (Director · Jul 24, 2018 – Jun 20, 2024 · Past); Osi Pharmaceuticals Inc (Director · Jun 14, 2006 – Jun 7, 2010 · Past); CV Therapeutics Inc (Director · Jun 6, 2006 – Apr 14, 2009 · Past); NPS Pharmaceuticals Inc (Director · Jan 17, 2006 – May 22, 2007 · Past)
Director · Nov 1, 2010 – May 15, 2024 · Past
Edward M. Kaye
Other companies: Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Stoke Therapeutics, Inc. (Director · Since at least Jun 18, 2019); Sarepta Therapeutics, Inc. (Chair of Scientific Advisory Board · Apr 24, 2012 – Nov 4, 2026 · Past)
Director · Since at least May 18, 2016
James Daly
Other companies: Halozyme Therapeutics, Inc. (Director · Since Sep 30, 2026); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2025); ACADIA Pharmaceuticals Inc. (Director · Since at least May 29, 2025)
Director · Since at least Aug 19, 2025
Muna Bhanji
Other companies: Intellia Therapeutics, Inc. (Independent Director · Since at least Apr 28, 2022); Veracyte, Inc. (Director · Since at least Mar 19, 2021); Ardelyx, Inc. (Director · Since at least Mar 11, 2021)
Director · Since at least Feb 17, 2021
Robert E. Landry
Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 5, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Regeneron Pharmaceuticals, Inc. (EVP Finance CFO · Mar 31, 2022 – Feb 2, 2024 · Past)
Director · Since at least Feb 10, 2025
Sung Lee
Other companies: Tango Therapeutics, Inc. (Executive Vice President and Chief Financial Officer, Cytokinetics · Since at least Jan 2, 2026); Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Mar 27, 2023 – Mar 27, 2024 · Past); Sangamo Therapeutics, Inc. (EVP, Chief Financial Officer · Oct 31, 2019 – Nov 25, 2020 · Past)
EVP, Chief Financial Officer · Since at least Apr 26, 2024
Caryn Gordon McDowell
Other companies: Quince Therapeutics, Inc. (Chief Legal & Adm. Officer · May 5, 2020 – Jun 6, 2022 · Past); Revance Therapeutics, Inc. (SVP, GC & Secretary · May 1, 2018 – Feb 15, 2020 · Past)
GC & Chief Compliance Officer · May 18, 2016 – Feb 27, 2018 · Past
Peter S Roddy
Other companies: Filana Therapeutics, Inc. (Chief Financial Officer · May 1, 2010 – Apr 8, 2016 · Past); Aspira Women's Health Inc. (Director · Feb 18, 2010 – Mar 17, 2016 · Past)
SVP Finance & CAO · Feb 8, 2018 – Feb 27, 2018 · Past
All 32 people
PersonSeat
Wendell Wierenga
Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jun 18, 2026); Dermata Therapeutics, Inc. (Director · Since at least Aug 12, 2021)
Director · Since at least Oct 15, 2025
Bonnie Charpentier
Other companies: Genitope Corp (VP of Regulatory Affairs · Dec 31, 2005 – Apr 27, 2006 · Past)
SVP Regulatory & Compliance · Jan 2, 2014 – Feb 28, 2017 · Past
Brett A Pletcher
Other companies: Gilead Sciences, Inc. (EVP,Corp Affairs & Gen Counsel · May 9, 2018 – Jun 10, 2022 · Past)
EVP, Chief Legal Officer · Aug 13, 2024 – Aug 30, 2024 · Past
Fady I. Malik
Other companies: Rocket Pharmaceuticals, Inc. (Independent Director · Since at least Mar 10, 2022)
EVP, Research & Development · Since at least Jun 1, 2012
Jeff Hessekiel
Other companies: Exelixis, Inc. (EVP & General Counsel · May 15, 2025 – May 15, 2025 · Past)
Chief Legal & Admin Officer · Since at least Nov 13, 2025
Mark A Schlossberg
Other companies: Impax Laboratories Inc (SVP and General Counsel · Feb 26, 2018 – May 4, 2018 · Past)
SVP - Legal & General Counsel · Jan 14, 2019 – Mar 15, 2022 · Past
Michael Rabson
Other companies: Maxygen Inc (Senior Vice President · Jan 3, 2006 – Feb 1, 2008 · Past)
SVP Business Dev/Legal & GC · Mar 31, 2008 – Dec 18, 2009 · Past
Andrew CallosEVP, Chief Commercial Officer · Since at least Mar 15, 2021
Bradley Paul MorganSVP Drug Discovery & Early Dev · Nov 16, 2015 – Aug 31, 2017 · Past
Ching JawSVP Finance & CFO · Jun 26, 2017 – Mar 6, 2023 · Past
Diane WeiserSVP, Corporate Affairs · Since at least Nov 3, 2026
Elisabeth A. SchniedersSVP, Business Development · Since at least Nov 5, 2026
Isaac CiechanoverEVP, Corporate Development & Chief Business Officer · Since at least Nov 5, 2026
John FaurescuSVP, Deputy General Counsel & Corporate Secretary · Since at least Nov 5, 2026
John T. HendersonDirector · Since at least Apr 15, 2025
Nancy J. WysenskiDirector · Since at least Apr 15, 2026
Robert A. HarringtonDirector · Since at least Apr 8, 2022
Robert I. BlumPresident & CEO, Director · Since at least Apr 1, 2026
Robert WongVP, Chief Accounting Officer · May 15, 2019 – Dec 3, 2024 · Past
Sandford D SmithDirector · Apr 1, 2022 – Jan 2, 2024 · Past
Stephen B. HeitnerSVP, Chief Medical Officer · Since at least Oct 12, 2026
Tricia OttavianiSVP, U.S. & Global Marketing and Operations · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Cytokinetics, Incorporated.